Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001339846 | SCV001533621 | uncertain significance | Transcobalamin I deficiency | 2020-09-09 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with valine at codon 115 of the TCN1 protein (p.Asp115Val). The aspartic acid residue is weakly conserved and there is a large physicochemical difference between aspartic acid and valine. This variant is present in population databases (rs780641711, ExAC 0.09%). This variant has not been reported in the literature in individuals with TCN1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004035914 | SCV003952330 | uncertain significance | not specified | 2023-04-19 | criteria provided, single submitter | clinical testing | The c.344A>T (p.D115V) alteration is located in exon 3 (coding exon 3) of the TCN1 gene. This alteration results from a A to T substitution at nucleotide position 344, causing the aspartic acid (D) at amino acid position 115 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |